Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, ...

Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Valeant got into trouble nearly a decade ago after using debt to ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential ... the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.